- |||||||||| Journal: Management strategies for severe Pseudomonas aeruginosa infections. (Pubmed Central) - Oct 12, 2023
Combination therapy does not reduce mortality, but may be necessary for empirical treatment. Short-term treatment of severe P. aeruginosa infections should be preferred when it is expected that the clinical situation resolves rapidly.
- |||||||||| Journal: Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era-Challenges and Solutions. (Pubmed Central) - Aug 26, 2023
KPC-producing isolates were also highly susceptible to colistin (92%)...ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions.
- |||||||||| Journal: Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil. (Pubmed Central) - Jul 29, 2023
The most active drug was cefiderocol (100%), followed by ceftazidime-avibactam (94.1%), ceftolozane-tazobactam (92.4%), and imipenem-relebactam (81.5%)...Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years.
- |||||||||| Review, Journal, Gram negative: Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review. (Pubmed Central) - Jul 29, 2023
Nonetheless, several novel agents lack pediatric indications approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), leading to uncertain pediatric-specific treatment strategies and uncertain dosing regimens in the pediatric population. In this narrative review we have summarized the available clinical and pharmacological data, current limitations and future prospects of novel beta lactam antibiotics in the pediatric population.
- |||||||||| imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 ?-Lactamase. (Pubmed Central) - May 27, 2023 We note also that antibiotic activity is influenced by genotypes and that understanding the geographic region's molecular epidemiology could aid in the definition of the presumptive utility of novel agents and contribute to antibiotic decision-making. Imipenem-relebactam overcame the resistance of the D179 variants, suggesting that this combination will be active against clinical isolates harboring these derivatives of KPC-2.
- |||||||||| imipenem/relebactam / Merck (MSD), Fetroja (cefiderocol) / Shionogi, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Combination therapy, Gram negative: Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. (Pubmed Central) - May 27, 2023 Moreover, the combination of CAZ-AVI/SULB showed synergistic activity in CAZ-AVI-resistant CRE strain. In conclusion, although further analyses are needed to confirm these results, our work showed the efficacy of CFD when used for synergistic formulations.
- |||||||||| Review, Journal: What to Do with the New Antibiotics? (Pubmed Central) - Apr 28, 2023
Knowledge of the risk factors for multidrug-resistant Gram-negative bacilli (local ecology, prior colonization, failure of prior antibiotic therapy, and source of infection) seems necessary in order to optimize antibiotic prescriptions. In this review, we will assess these different antibiotics according to the epidemiological data.
- |||||||||| aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie, imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and ?-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa. (Pubmed Central) - Apr 17, 2023 Moreover, the susceptibility breakpoints of ceftazidime, aztreonam, and imipenem were reached using the triple combination of chimera 4 with ceftazidime/avibactam, aztreonam/avibactam, and imipenem/relebactam, respectively, against ?-lactamase-harboring P. aeruginosa. Our findings demonstrate that tobramycin-based chimeras form a novel class of antibiotic potentiators capable of restoring the activity of antibiotics against P. aeruginosa.
- |||||||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam. (Pubmed Central) - Apr 11, 2023 Thirty-three (11.2%) P. aeruginosa isolates were resistant to both carbapenems and 30 (10.2%) P. aeruginosa showed resistance to ?3 antimicrobials/antimicrobial groups (among piperacillin-tazobactam, ceftazidime, tobramycin, carbapenems, and fluoroquinolones)...Only two K. pneumoniae and four P. aeruginosa isolates were resistant to all three beta-lactam/beta-lactamase-inhibitor combinations. However, this favorable result should be viewed in light of the relatively low prevalence of MDR organisms that require these agents in Germany.
- |||||||||| Journal, Gram negative: Treatment options for multidrug-resistant Gram-negatives in urinary tract infections. (Pubmed Central) - Apr 4, 2023
However, this favorable result should be viewed in light of the relatively low prevalence of MDR organisms that require these agents in Germany. To ensure prudent use and to avoid the development of resistance to novel anti-infective substances, an interdisciplinary approach, including urologists, microbiologists, and infectious disease physicians, is strongly advised.
|